Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aspartate transaminase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    596 result(s) found for: Aspartate transaminase. Displaying page 4 of 30.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-005141-32 Sponsor Protocol Number: MYL-1402O-3001 Start Date*: 2016-07-11
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous...
    Medical condition: Stage IV unresectable, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) HR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004693-27 Sponsor Protocol Number: A6181064 Start Date*: 2006-11-09
    Sponsor Name:Pfizer Ltd.
    Full Title: A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS
    Medical condition: Advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) AT (Prematurely Ended) SE (Prematurely Ended) FI (Completed) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003517-95 Sponsor Protocol Number: OP-103 Start Date*: 2017-01-31
    Sponsor Name:Oncopeptides AB
    Full Title: A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to...
    Medical condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Temporarily Halted) BE (Completed) DK (Completed) NL (Completed) NO (Completed) FR (Completed) PL (Completed) AT (Completed) EE (Completed) LT (Completed) IT (Completed) RO (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2010-020341-27 Sponsor Protocol Number: GFM-Aza intensif Start Date*: 2010-06-22
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017178-19 Sponsor Protocol Number: GFM- Aza-Ida-09 Start Date*: 2010-09-14
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019709-41 Sponsor Protocol Number: GFM-Aza-ceplene Start Date*: 2010-10-13
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interl...
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006713-16 Sponsor Protocol Number: CP12-0604 Start Date*: 2008-09-02
    Sponsor Name:ImClone Systems Incorporated
    Full Title: Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma
    Medical condition: Metastatic Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000930-37 Sponsor Protocol Number: M15-722 Start Date*: 2018-12-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003385-84 Sponsor Protocol Number: GO40782(RXDX-101-02) Start Date*: 2016-03-15
    Sponsor Name:F. Hoffman-La Roche Ltf
    Full Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRA...
    Medical condition: Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002763-25 Sponsor Protocol Number: NT2013/Orv/Prot001 Start Date*: 2013-10-11
    Sponsor Name:NeRRe Therapeutics Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in on...
    Medical condition: Intense pruritus, in oncology subjects, induced by EGFRi
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10023084 Itching LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001270-27 Sponsor Protocol Number: A6181061 Start Date*: 2005-08-17
    Sponsor Name:PFIZER LTD
    Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CARCINOMA
    Medical condition: Histologically confirmed renal cell carcinoma with metastases with a component of clear (conventional) cell histology
    Disease: Version SOC Term Classification Code Term Level
    7,1 10038415
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001459-28 Sponsor Protocol Number: IMM-101-011 Start Date*: 2016-12-08
    Sponsor Name:Immodulon Therapeutics Ltd
    Full Title: A Novel Phase I/IIa Open label Study of IMM 101 in Combination with Selected Standard of Care (SOC) Regimens in Patients with Metastatic Cancer or Unresectable Cancer at Study Entry.
    Medical condition: Metastatic Cancer or Unresectable Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028980 Neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000476-33 Sponsor Protocol Number: GC-SU-2006 Start Date*: 2006-11-20
    Sponsor Name:Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik
    Full Title: An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer
    Medical condition: Chemorefractory metastatic adenocarcinoma of stomach, esophagogastric junction and lower esophagus (Barrett carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003804-66 Sponsor Protocol Number: ABI-007-NSCL-003 Start Date*: 2015-10-22
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB-PACLITAXEL (ABRAXANE®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB-PACLITAXEL PLUS CARBOPLATIN IN S...
    Medical condition: Squamous Cell Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004461-47 Sponsor Protocol Number: DV3-MEL-01[SYNERGY-001] Start Date*: 2017-07-10
    Sponsor Name:Dynavax Technologies Corporation
    Full Title: A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastati...
    Medical condition: Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001346-34 Sponsor Protocol Number: IMM-101-015 Start Date*: 2018-07-27
    Sponsor Name:Immodulon Therapeutics Ltd
    Full Title: A Study of the Safety and Efficacy of IMM-101 in Combination with Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma
    Medical condition: Unresectable, Stage III or Stage IV metastatic melanoma who are either previously untreated (cohort A), or whose disease has progressed during PD-1 blockade (cohort B).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028980 Neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-003364-36 Sponsor Protocol Number: GED-0301-UC-002 Start Date*: 2016-02-09
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects with Active Ulcerative Colitis.
    Medical condition: Ulcerative Colitis.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000478-31 Sponsor Protocol Number: OP-107 Start Date*: 2018-07-09
    Sponsor Name:Oncopeptides AB
    Full Title: A Study of the Pharmacokinetics of Melphalan During Treatment with Melflufen and Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma and Impaired Renal Function
    Medical condition: Patients with Relapsed Refractory Multiple and Impaired Renal Function
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009457-13 Sponsor Protocol Number: StudyITCC020&I-BFMRelapsedAML Start Date*: 2009-07-30
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
    Medical condition: Relapsed/refractory acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066638 Acute myeloid leukemia progression LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006115-19 Sponsor Protocol Number: SB17-3001 Start Date*: 2021-06-11
    Sponsor Name:Samsung Bioepis Co., Ltd
    Full Title: A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (proposed ustekinumab biosimilar) Comp...
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) PL (Completed) LT (Completed) HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 08:08:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA